The company has submitted its application for its Candida auris test to the Food and Drug Administration (FDA). It’s seeking Breakthrough Device designation as it plans to add the test to its FDA-cleared T2Candida Panel.
Candida auris is of major concern to those in the healthcare field as it has a mortality rate of up to 60%. This has prompted the Centers for Disease Control and Prevention () and the World Health Organization (WHO) to declare it a serious global health threat.
Candida auris is a multidrug-resistant fungal pathogen. Considering its mortality rate, T2 Biosystems believes adding it to its T2Candida Panel would be a major boon to healthcare workers. That’s due to its ability to identify five variants of Candida species without having to wait days for a positive blood culture.
How This Affects TTOO Stock
Investors are excited about the prospect of the FDA granting T2 Biosystems Breakthrough Device designation for the Candida auris test. If it does, it could act as a major catalyst sending shares of TTO stock higher.
Traders are already seeing heavy trading for TTOO stock today on the submission announcement. This has more than 44 million shares of the stock changing hands as of this writing. That’s a massive surge compared to its daily average trading volume of about 10 million shares.
TTOO stock is up 17.1% as of Tuesday morning.
Investors seeking even more of the most recent stock market news will want to stick around!
InvestorPlace has all of the hottest stock market news traders need to know about on Tuesday! Our coverage includes why shares of Visionary Education Tech (NASDAQ:VEDU) stock are up, the biggest pre-market stock movers this morning, and more. We’ve got all of that news ready to go below!
More Stock Market News For Tuesday
- Why Is Visionary Education Tech (VEDU) Stock Up 55% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- SEV Stock: There Are No Sono Motor Shares Available to Short
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.